A multicenter, randomized, parallel controlled clinical study of Chuanbei Qing - Magnesium sulfate sodium sulfate and potassium sulfate concentrate oral solution for intestinal preparation before colonoscopy in adult patients

开始日期2023-10-15

申办/合作机构-

NCT06051955 / RecruitingN/AIIT

Evaluation of an Oral Sodium Sulfate Solution for Patients With Prior Difficult or Incomplete Cleansing, a Progressive Case Series.

This case series aims to evaluate the effectiveness and tolerability of Oral Sulfate Solution (OSS) in patients who had previously experienced poor colonoscopy preparation.

开始日期2023-10-11

申办/合作机构

Queen's University

[+1]

NCT05877911 / Not yet recruiting临床2期IIT

Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy: a Multi-center Prospective Randomized Controlled Trial.

Ovarian cancer is the most lethal malignancy of the female genital tract. Cytoreductive surgery combined with chemotherapy is the primary treatment for ovarian cancer, and radical tumor resection is an important means to improve the prognosis. However, even after complete tumor resection, 75% of patients with ovarian cancer still recur within 3 years after the initial treatment and eventually die from recurrence. In ovarian cancer, the lesions are located primarily in the peritoneal cavity. High-grade evidence demonstrates that the use of intraperitoneal hyperthermic chemotherapy (HIPEC) with cisplatin after cytoreductive surgery significantly improves the outcome in some patients with ovarian cancer. Currently, this is the only non-pharmacologic treatment that reduces both the risk of recurrence and death from ovarian cancer with a multi treatment. However, HIPEC with cisplatin can lead to acute kidney injury, and a serious complication that can seriously affect the short and long-term prognosis of patients. Sodium thiosulfate has previously been reported to reduce the incidence of acute kidney injury after HIPEC with cisplatin, but this finding has not been confirmed in a high-level study. Therefore, we propose a multi-center, prospective, open-label, randomized, controlled trial including 110 patients with ovarian cancer who received HIPEC with cisplatin, to evaluate whether sodium thiosulfate combined with hydration (55 patients in the trial group) can reduce the incidence of acute kidney injury after HIPEC with cisplatin compared with hydration alone (55 patients in the control group), and to provide high-level evidence for the rationale of using sodium thiosulfate for nephrotoxicity relief in cisplatin HIPEC.

开始日期2023-05-01

申办/合作机构

Sun Yat-Sen Memorial Hospital

[+2]

100 项与 Sodium Sulfate 相关的临床结果

登录后查看更多信息

100 项与 Sodium Sulfate 相关的转化医学

登录后查看更多信息

100 项与 Sodium Sulfate 相关的专利（医药）

登录后查看更多信息

1,932

项与 Sodium Sulfate 相关的文献（医药）

2024-05-01·Talanta

A novel synchronous fluorescence spectrometry combined with fluorescence sensitization for the highly sensitive and simultaneous detection of enoxacin, ofloxacin and tetracycline hydrochloride residues in wastewater

Article

作者: Xie, Lingfang ; Wang, Menglin ; Zheng, Xiaodan ; Zhang, Shiqi ; Yangcuo, Zhima ; Cai, Qihong

The synergistic effect of sodium dodecyl sulfate (SDS) and Mg²⁺ could significantly enhance the fluorescence intensity of enoxacin (ENO) at λ_ex/λ_em = 269.2 nm/385.6 nm, ofloxacin (OFL) at λ_ex/λ_em = 290.8 nm/466.2 nm and tetracycline hydrochloride (TCH) at λ_ex/λ_em = 372.6 nm/514.8 nm. Moreover, when the wavelength difference (Δλ) was chosen 135 nm, the synchronous fluorescence spectra of the three antibiotic complexes could be well separated and the interference of the samples matrix were eliminated primely. Therefore, only one synchronous fluorescence scan was needed to simultaneously determine the three antibiotics. Based on these facts, a synchronous fluorescence spectrometry combining fluorescence sensitization for highly sensitive and selective determination of ENO, OFL and TCH residues in wastewater was developed for the first time. The experimental results showed that the concentrations of ENO, OFL and TCH in the range of 0.5-550 ng mL^-1, 1-1500 ng mL^-1 and 10-5500 ng mL^-1 showed a good linear relationship with fluorescence intensity. The limits of detection were 0.0599 ng mL^-1, 0.115 ng mL^-1 and 0.151 ng mL^-1, respectively. The recoveries of the actual sample were 87.50%-99.99 %, 93.00%-98.50 % and 85.70%-98.42 %, respectively. Overall, the novel synchronous fluorescence spectrometry established in the experiment has the advantages of high sensitivity, good selectivity, fast detection speed and high accuracy. It has been successfully applied to the detection of residual amounts of ENO, OFL and TCH in wastewater with satisfactory results.

2024-04-01·Environmental research

RETRACTED: Construction of self-repairing polyethersulfone membrane with high density hydrophilic microregions by two dimensional restricted channels for enhanced dyes/salts selective separation

Article

作者: Wu, Junyong ; Wu, Leixin ; Chen, Weibin ; Liu, Shenghui ; Theliander, Anette ; Zhang, Jintuan

Based on the dye/salts separation efficiency and membrane injury caused by serious pollution of dye/salts wastewater, this study constructed a 2D tight ultrafiltration membrane that could both solve the membrane injury problem and improve the dye/salts separation efficiency, the compatibility of good self-healing performance and penetration performance by 2D material magnesium-aluminum Layered double hydroxide (MgAl-LDH). The self-repairing of physical injury was achieved through the swelling effect of AMPS-PAN, this property was proved by permeate flux, the retention performance of salts in dye/salts solution, the comparison of scanning electron microscope (SEM), and the mechanical strength after physical injury. The healing of chemical injury occured through the reaction of CC and polyethersulfone chain breakage, which was confirmed by X-ray photoelectron spectroscopy (XPS), permeate flux, the retention performance of salts in dye/salts solution, and mechanical property. The high separation efficiency of dye/salts was achieved through 2D material MgAl-LDH, which was proved by separation selectivity ɑ. The compatibility of good self-healing performance and penetration performance was obtained by 2D material MgAl-LDH, which was proved by the penetration and self-healing performance. Morever, the membrane illustrated excellent both permeability and dye/sals separation efficiency, just like the permeate flux, the retention performance of sodium sulfate in methyl blue/sodium sulfate solution, the retention performance of Na₂SO₄ in methyl blue/Na₂SO₄ solution, the retention rate of methyl blue were 99.1 L/m²h, 12.5%, 7.9%, 97.7%, respectively. The results of pollution index and contact angle also proved that the membrane had anti-pollution performance.

2024-04-01·Biosensors & bioelectronics

Innovative approaches to suppress non-specific adsorption in molecularly imprinted polymers for sensing applications

Article

作者: Amine, Aziz ; Karrat, Abdelhafid

Molecularly imprinted polymers (MIPs) are synthetic antibodies developed to bind selectively with specific molecules. They function through a particular recognition process involving their cavities and functional groups. Nevertheless, functional groups located outside these cavities are the main cause of non-specific molecule binding, thus reducing the effectiveness of MIPs in sensing applications. This work focused on enhancing the selectivity and performance of MIPs through electrostatic modification with surfactants. The study investigates the use of two surfactants, namely sodium dodecyl sulfate (SDS) and cetyl trimethyl ammonium bromide (CTAB), to eliminate non-specific adsorption in MIPs. The binding isotherms of the target molecule sulfamethoxazole (SMX) on MIPs and non-imprinted polymers (NIPs) were analyzed, showing higher adsorption capacity of MIPs due to the specific cavities. The modification with SDS or CTAB effectively eliminated non-specific adsorption in MIPs. The kinetic adsorption behavior further demonstrated the efficacy of MIP^+--SDS/CTAB in the selective adsorption of SMX. Calibration curves showcase the methodology's analytical capabilities, achieving low limit of detection for SMX 6 ng mL^-1 using MIP ⁺-SDS. The stability study confirmed that the developed MIP ⁺^/^--SDS/CTAB remains stable even at high temperatures, demonstrating its suitability for on-site applications. The methodology was successfully applied to detect SMX in milk and water samples, achieving promising recoveries. Overall, the electrostatic modification of MIPs with surfactants emerges as a valuable strategy for enhancing selectivity and performance in target molecule recognition and detection.

项与 Sodium Sulfate 相关的新闻（医药）

2023-08-30

·Science Daily

Direct formation of sulfuric acid in the atmosphere

In the atmosphere, gaseous sulfuric acid can form particles that influence the physical properties of clouds. Thus, the formation of sulfuric acid in the gas phase directly affects the radiative forcing and Earth's climate. In addition to the known formation from sulfur dioxide, researchers have now been able to demonstrate through experiments that there is another formation pathway that has been speculated about for decades. Sulfuric acid in the atmosphere can also be formed directly by the oxidation of organic sulfur compounds. This new production pathway can be responsible for up to half of the gaseous sulfuric acid formation over the oceans and is thus of high importance for climate projections -- especially over the oceans of the Southern Hemisphere. In the atmosphere, gaseous sulfuric acid can form particles that influence the physical properties of clouds. Thus, the formation of sulfuric acid in the gas phase directly affects the radiative forcing and Earth's climate. In addition to the known formation from sulfur dioxide, researchers at the Leibniz Institute for Tropospheric Research (TROPOS) have now been able to demonstrate through experiments that there is another formation pathway that has been speculated about for decades. Sulfuric acid in the atmosphere can also be formed directly by the oxidation of organic sulfur compounds. This new production pathway can be responsible for up to half of the gaseous sulfuric acid formation over the oceans and is thus of high importance for climate projections -- especially over the oceans of the Southern Hemisphere, as the researchers write in the journal Nature Communications. Organic sulfur compounds are mainly emitted from biogenic sources and contribute significantly to Earth's sulfur cycle. The sulfur cycle is important for Earth's climate because the oxidation products of organic sulfur compounds, such as sulfuric acid (H2SO4) and methanesulfonic acid (MSA, CH3SO3H), initiate new particle formation. Sulfate particles scatter incoming solar radiation efficiently and affect the formation of cloud condensation nuclei (CCN). Number and size of CCN significantly change the microphysical and radiative properties as well as the lifetime of clouds. Hence, knowledge of how H2SO4 is formed in the atmosphere is mandatory to understand fundamental processes in the climate system. On global scale, with an annual emission rate of about 30 million tons of sulfur, the most important organic sulfur compound is dimethyl sulfide (DMS, CH3SCH3) followed by methyl mercaptan (MeSH, CH3SH) and, to a lesser extent, dimethyl disulfide (DMDS, CH3SSCH3). Numerous laboratory experiments and model simulations were performed at TROPOS to investigate the atmospheric oxidation pathways of these compounds. "To our knowledge, there is so far no experimental evidence for the direct formation of H2SO4 in the gas phase, except via SO2 oxidation by OH radicals or Criegee intermediates, although this has long been speculated about in the literature and even such pathways are implemented in models," explains Dr. Torsten Berndt of TROPOS. At TROPOS, experimental proof of direct H2SO4 formation has now been achieved, using two flow systems: a horizontal free-jet flow system and a vertical laminar flow tube. With these systems, it was possible to work under different reaction conditions, which allowed an exact investigation of the oxidation processes by using advanced mass spectrometric techniques. In addition, the experimental findings allow the estimation of many kinetic parameters in the sulfur oxidation cycle and thus contribute to an improved understanding of its atmospheric oxidation. The experimental results were integrated into the complex multiphase chemistry mechanism MCM/CAPRAM existing at TROPOS for model evaluation. "Under the relatively pristine conditions over the Southern oceans, the direct formation of H2SO4 can contribute up to 50% to the total gas phase formation," report Dr. Andreas Tilgner and Dr. Erik H. Hoffmann. It is postulated that the direct gas-phase formation may be especially important over oceans in the Southern Hemisphere. These regions are often characterized by small SO2-to-DMS ratios, which means that the fraction of this direct production pathway can be important there. Other atmospheric regions, where small SO2-to-DMS ratios are expected, are in the outflow regimes of marine clouds. There, high H2SO4 concentrations and the formation of new aerosol particles have been already observed, which can now be explained.

2023-08-11

·Coatings World

Induron Protective Coatings Launches New NOVALAC Epoxy

Induron Protective Coatings announces the launch of its newest product, Novasafe. Novasafe is a furfuryl modified, thick film, ceramic-filled novolac epoxy and it can stand up to the most extreme environments encountered in treatment plants. “Water and wastewater treatment plant owners, operators, and engineers are under more pressure than ever to protect our national water infrastructure,” said William Seawell, Induron technical service manager. “In a period of increased influent volume, more chemically extreme influent, and increasing regulatory pressure, there is an increasing need for longer immersion coating service lives. “For years, Induron’s method of choice for protecting buried ductile iron pipe interiors, water tank interiors and water treatment plant interiors has been thick film ceramic epoxy technology,” Seawell added. “In response to industry challenges, Induron is bringing that same technology to the most extreme service environments encountered in treatment plants with its introduction of Novasafe ceramic novolac.” Novasafe’s formulation chemistry is unique in the industry, and it is able to accomplish what treatment plant operators need in the most extreme environments with one less coat compared to traditional epoxies and less film thickness than polyurethane/polyurea. Novasafe is able to accomplish this with its unique resin and filler package. As a benchmark of performance, Novasafe is able to withstand exposure to sulfuric acid at all concentration ranges for extended periods of time. Many industry novolacs can withstand dilute or 98% sulfuric acid but the range of 93-97% has historically been problematic for un-baked novolac products— even in the oil and gas industries where this is a significant issue. “While Novasafe is not appropriate for all services—no lining material is— there is a place in every treatment plant specification or treatment plant where Novasafe can assist in providing long-term asset protection, reducing maintenance load, saving maintenance dollars and improving the look of the facility,” said Davies Hood, Induron president.

2023-06-22

·PRNewswire

FDA Approves Sebela Pharmaceuticals' SUFLAVE™ A New Colonoscopy Preparation that Tastes Similar to a Sports Drink

SUFLAVE™ offers the same efficacy as SUPREP® Bowel Prep Kit BRAINTREE, Mass., June 22, 2023 /PRNewswire/ -- Sebela Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) granted approval of SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution), for colonoscopy preparation in adults. SUFLAVE, a low-volume, safe and effective colonoscopy preparation – with a taste similar to a lemon-lime sports drink – was developed and will be marketed by Braintree Laboratories, a leader in gastroenterology and part of Sebela Pharmaceuticals. The current active screening rate in the United States for colorectal cancer (CRC) is 72%, leaving 28% unscreened, which contributes to 153,000 CRC diagnoses and more than 52,000 deaths annually.i,ii Colonoscopy is the most common detection method for colorectal cancer, a leading cause of cancer-related deaths that can be managed more effectively through screening and early detection.iii Successful colonoscopy screening is dependent upon adequate cleansing of the colon.iv Despite this, available methods of liquid preparation are not widely accepted by patients due to large volumes of poor-tasting solutions, resulting in low patient compliance and the need for repeat screenings. Additionally, colonoscopy preparation products and processes are commonly cited as a significant patient barrier to colon cancer screening,v reinforcing an unmet need among patients for better bowel preparation options. Tolerance of bowel preparation remains the largest deterrent for patients considering screening colonoscopy with 71% of patients saying it's the worst part of colonoscopy and 55% indicating it was the greatest deterrent to a future colonoscopy.vi Prep volume, palatability and patient education are three key factors in reducing prep hesitancy. "Patients frequently struggle with the taste and volume of traditional bowel preparations – and fear related to the preparation can also negatively impact patient willingness to undergo follow-up colonoscopy if it is indicated," said Douglas K. Rex, M.D., Distinguished Professor Emeritus at Indiana University School of Medicine and a full time practicing clinical gastroenterologist. "I believe the palatable lemon-lime flavor of SUFLAVE will be a welcomed option for patients – reducing preparation hesitancy and giving more people the chance to feel comfortable during preparation and getting a successful and effective procedure." In a head-to-head pivotal study versus SUPREP® Bowel Prep Kit, (sodium sulfate, potassium sulfate, and magnesium sulfate) Oral Solution, 94% of patients achieved successful bowel cleansing with SUFLAVE. The majority of patients reported that SUFLAVE tastes like a sports drink, and 79% of patients found the taste neutral to very pleasant compared to SUPREP (54%). Additionally, 87% of patients found SUFLAVE tolerable to very easy to consume, and 80% of patients reported that they would ask for SUFLAVE for a subsequent colonoscopy. Rates of gastrointestinal adverse events with SUFLAVE were low (<8%).vii "We believe in patient choice and are committed to improving the colon preparation process for patients. We are delighted with the FDA's approval of SUFLAVE – which has efficacy equivalent to SUPREP, but with taste similar to a sports drink," said Alan Cooke, President and CEO of Sebela Pharmaceuticals. "We are proud of the hard work and dedication of the Braintree team and the phase 3 trials investigator group who continue to bring new, better choices to people undergoing colonoscopy screening." SUFLAVE is the latest innovation in colonoscopy preparation from Braintree Laboratories. In November 2020, the FDA approved the company's tablet preparation, SUTAB®, which has had an excellent adoption record with use by over 2 million patients. SUFLAVE will be available by prescription to patients in the U.S. in early August. IMPORTANT SAFETY INFORMATION SUFLAVE™ (polyethylene glycol, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. DOSAGE AND ADMINISTRATION: A low residue breakfast may be consumed on the day before colonoscopy, followed by clear liquids up to 2 hours prior to colonoscopy. Administration of two doses of SUFLAVE are required for a complete preparation for colonoscopy. Each bottle must be reconstituted with water before ingestion. Each bottle and one flavor-enhancing packet are equivalent to one dose. An additional 16 ounces of water must be consumed after each dose. Stop consumption of all fluids at least 2 hours before the colonoscopy. CONTRAINDICATIONS: Use is contraindicated in the following conditions: Gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUFLAVE. WARNINGS AND PRECAUTIONS: Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration; Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur. ADVERSE REACTIONS: Most common adverse reactions (> 2%) are: nausea, abdominal distension, vomiting, abdominal pain, and headache. DRUG INTERACTIONS: Drugs that increase risk of fluid and electrolyte imbalance. See Full Prescribing Information and Medication Guide About Sebela Pharmaceuticals Sebela Pharmaceuticals is a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women's health. Braintree, a part of Sebela Pharmaceuticals, is the market leader in colonoscopy screening for over 35 years, having invented, developed and commercialized a broad portfolio of innovative prescription colonoscopy preparations and multiple gastroenterology products. Braintree also has multiple gastroenterology programs in late-stage clinical development including Tegoprazan which is in phase 3 trials for gastro-esophageal reflux disease (GERD), specifically, erosive esophagitis (EE) and non-erosive reflux disease (NERD). In addition, Sebela Women's Health has two next generation intra-uterine devices (IUDs) for contraception in the final stages of clinical development. Sebela Pharmaceuticals has offices/operations in Roswell, GA; Braintree, MA; and Dublin, Ireland; has annual net sales of approximately $200 million; and has grown to over 320 employees through strategic acquisitions and organic growth. Please visit sebelapharma.com for more information or call 800-874-6756. Forward-looking Statements This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sebela Pharmaceuticals under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of SUFLAVE™; growth and opportunity, including peak sales and the potential demand for SUFLAVE™, as well as its potential impact on applicable markets; market size; substantial competition; our ability to continue as a growing concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third-party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or otherwise as expected; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Sebela Pharmaceuticals does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law. For further information, contact: Logan Campbell, Red Havas [email protected] 1-724-987-2781 ______________ i Centers for Disease Control and Prevention. (2023, March 22). Colorectal (colon) cancer statistics. Center for Disease Control and Prevention. Retrieved June 12, 2023, from ii Colorectal cancer – statistics. Cancer.net (2023, February). Retrieved June 12, 2023, from iii Doubeni CA, Corley DA, Quinn VP, et al. Effectiveness of screening colonoscopy in reducing the risk of death from right and left colon cancer: a large community-based study. Gut. 2018;67(2):291-298 iv Harrison, N. M., & Hjelkrem, M. C. (2016). Bowel cleansing before colonoscopy: Balancing efficacy, safety, cost and patient tolerance. World journal of gastrointestinal endoscopy, 8(1), 4–12. v Romero, R. V., & Mahadeva, S. (2013). Factors influencing quality of bowel preparation for colonoscopy. World journal of gastrointestinal endoscopy, 5(2), 39–46. vi emulapalli KC, Lahr RE, Rex DK. 2021 Patient Perceptions Regarding Colonoscopy Experience. J Clin Gastroenterol. 2023 Apr 1;57(4):400-403. doi: 10.1097/MCG.0000000000001689. PMID: 35324481. vii Data on File, Braintree, MA: Braintree Laboratories, Inc. SOURCE Sebela Pharmaceuticals

临床3期临床结果上市批准

100 项与 Sodium Sulfate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05877	-	A06AD13 A12CA02	DB09472

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
ST段抬高心肌梗死	临床2期	-	Mallinckrodt Plc	2009-12-01
冠心病	临床2期	澳大利亚	Mallinckrodt Plc	2009-05-01
冠心病	临床2期	加拿大	Mallinckrodt Plc	2009-05-01
氧自由基损伤	临床2期	澳大利亚	Mallinckrodt Plc	2009-05-01
氧自由基损伤	临床2期	加拿大	Mallinckrodt Plc	2009-05-01
心肌梗塞	临床2期	-	Fred Hutchinson Cancer Research Center	-
心肌缺血	临床2期	澳大利亚	Ikaria, Inc.	-
心肌缺血	临床2期	加拿大	Ikaria, Inc.	-
再灌注损伤	临床2期	澳大利亚	Ikaria, Inc.	-
再灌注损伤	临床2期	加拿大	Ikaria, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00995501 (CTgov)	N/A	炎症	381	Insulin+anesthesia management+Dexamethasone Sodium Sulfate (Intensive Glucose Control, Dexamethasone, Light Anesthesia)	積遞鹽糧壓醖艱製醖餘(糧齋艱顧鬱繭齋願鬱餘) = 衊蓋廠製鹹餘觸壓糧齋構範壓醖衊壓願鑰鏇範 (觸願廠壓繭築襯憲壓廠, 鹹鹹築選齋鹽鹹淵窪糧 ~ 壓醖願積獵淵顧選鬱蓋) 更多	-	2017-04-25
				Anesthesia management -Placebo+Dexamethasone Sodium Sulfate (Intensive Glucose Control, Dexamethasone, Deep Anesthesia)	積遞鹽糧壓醖艱製醖餘(糧齋艱顧鬱繭齋願鬱餘) = 壓鏇襯襯糧簾鹹壓齋觸構範壓醖衊壓願鑰鏇範 (觸願廠壓繭築襯憲壓廠, 願築繭鑰觸鏇壓憲遞壓 ~ 廠繭壓糧壓簾觸膚醖醖) 更多
NCT00879645 (CTgov)	临床1期	肾功能不全	28	Sodium Sulfide (Sodium Sulfide - Mild Cohort)	觸繭壓窪願遞遞積壓鏇(範齋餘廠膚夢廠製壓顧) = 夢憲製築壓網鏇獵築糧構獵醖鏇遞鹹願衊壓選 (窪範夢築壓繭簾簾窪糧, 齋襯築艱製夢願願製廠 ~ 網壓鏇鏇觸網襯壓鹽積) 更多	-	2010-11-04
				Sodium Sulfide (Sodium Sulfide - Healthy Cohort)	觸繭壓窪願遞遞積壓鏇(範齋餘廠膚夢廠製壓顧) = 構壓鏇壓獵夢顧窪遞簾構獵醖鏇遞鹹願衊壓選 (窪範夢築壓繭簾簾窪糧, 網鏇繭鹽憲製選鬱獵衊 ~ 獵餘艱遞範積鑰醖淵製) 更多